The Mechanistic or Mammalian Target of Rapamycin (mTOR) is a major signaling pathway in eukaryotic cells belonging to the P13K-related kinase family of the serine/threonine protein Target Matrix Estimators in Risk-Based Portfolios kinase.It has been established that mTOR plays a central role in cellular processes and implicated in various cancers, diabetes, and in the aging process with very poor prognosis.Inhibition of the mTOR pathway in the cells may improve the therapeutic index in cancer treatment.
Photodynamic therapy (PDT) has been established to selectively eradicate neoplasia at clearly delineated malignant Resilience-Improving Based Optimization of Post-Disaster Emergency Maintenance Strategy for Transmission Networks lesions.This review highlights recent advances in understanding the role or regulation of mTOR in cancer therapy.It also discusses how mTOR currently contributes to cancer as well as future perspectives on targeting mTOR therapeutically in cancer in vitro.